Plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to peripheral blood for collection and autologous transfusion in patients with lymphoma or multiple myeloma.
Plerixafor reversibly blocks the chemokine receptor CXCR4 to prevent binding of its ligand CXCL12 (stromal cell-derived factor-1α).
The drug is injected after four days of treatment with granulocyte-colony stimulating factor (G-CSF), 6-11 hours before initiation of apheresis. Following administration, both haematopoietic progenitor cells and mature leukocytes appear in the systemic circulation.
Further information: Genzyme